25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
11 citations
,
November 2018 in “British Journal of Dermatology” Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
8 citations
,
April 2011 in “Surgery today” A substance called sodium zinc dihydrolipoylhistidinate can significantly reduce hair loss caused by chemotherapy in rats.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
133 citations
,
November 2018 in “Aging” Azithromycin and Roxithromycin can remove aging cells and may help with anti-aging.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
1 citations
,
October 2022 in “Дерматовенерология Косметология” EGFR inhibitors for lung cancer can cause severe skin issues.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
September 2023 in “Journal of the American Academy of Dermatology” 15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
3 citations
,
May 2008 in “Journal of Clinical Oncology” Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
1 citations
,
October 2018 in “Infectious diseases in clinical practice” Azithromycin can rarely cause a severe drop in white blood cells.
6 citations
,
April 2016 in “Australasian journal of dermatology” Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
19 citations
,
December 2016 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” Certain drugs increase calcium levels in cancer cells by triggering internal calcium release.
2 citations
,
January 2021 in “JAAD Case Reports” Using a special laser and skin medication together successfully cleared a skin condition in a pregnant woman.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
June 2025 in “Clinical Cancer Research” Scalp cooling can effectively prevent hair loss during chemotherapy in pregnancy.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
11 citations
,
January 1999 in “Dermatology”
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.